Acrobosystems/Human Siglec-7/CD328蛋白，His标签/100ug/SG7
商品编号：
SG7
品牌：
ACROBiosystems
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
- SynonymCDw328， D-siglec， A79 membrane protein， p75，Adhesion inhibitory receptor molecule 1， AIRM-1
- SourceHuman Sigelc-7, His Tag (SG7-H5225) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Leu 353 (Accession # Q9Y286-1).Predicted N-terminus: Gln 19
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 38.8 kDa.
- Endotoxin
- Formulation
Please contact us for detailed information.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
- BackgroundSiglec-7 is a member of the human CD33‐related Siglec receptor. The extracellular region of Siglec‐7 is characterized by an N‐terminal V‐set Ig domain that can bind sialic acid and two C2‐set Ig domains. The cytoplasmic tail of Siglec‐7 has one immune‐receptor tyrosine‐based inhibitory motif (ITIM) and one ITIM‐like motif. Siglec-7 is considered as a sialic acid-dependent immunoreceptor with inhibitory potential and expressed predominantly on human NK cells, monocytes and a small subset of CD8+ T cells.
- References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
品牌介绍
ACROBiosystems 是一个具有全球范围影响力的生物技术领导品牌，其运营包括了位于北美、 欧洲和亚洲的数家公司， 主要为生命科学研究、生物制药与疫病诊断等行业提供产品、技术服务和临床应用等解决方案，同时致力于在蛋白组学、药物发现和细胞治疗等领域推广面向工业化和临床转化的技术和产品。ACROBiosystems 的业务遍及全球50多个国家和地区，并通过在北美、亚洲、欧洲等世界范围的不同时区设立分支机构以服务于当地客户与经销商。
